Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Tenzing Acquisition (TZAC) Competitors

TZAC vs. ORGS, AEZS, CPHI, NRBO, MTNB, CANF, NBY, SPRB, AFMD, and GRAY

Should you be buying Tenzing Acquisition stock or one of its competitors? The main competitors of Tenzing Acquisition include Orgenesis (ORGS), Aeterna Zentaris (AEZS), China Pharma (CPHI), NeuroBo Pharmaceuticals (NRBO), Matinas Biopharma (MTNB), Can-Fite BioPharma (CANF), NovaBay Pharmaceuticals (NBY), Spruce Biosciences (SPRB), Affimed (AFMD), and Graybug Vision (GRAY).

Tenzing Acquisition vs. Its Competitors

Tenzing Acquisition (NASDAQ:TZAC) and Orgenesis (NASDAQ:ORGS) are both small-cap pharmaceutical preparations industry companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

60.9% of Tenzing Acquisition shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 37.5% of Tenzing Acquisition shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Tenzing Acquisition's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Tenzing Acquisition Neutral
Orgenesis Neutral

Tenzing Acquisition has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Tenzing Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Tenzing AcquisitionN/A -13.32% -1.36%
Orgenesis -3,827.81%N/A -130.18%

Tenzing Acquisition has higher earnings, but lower revenue than Orgenesis.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tenzing AcquisitionN/AN/A$620KN/AN/A
Orgenesis$662K9.64-$55.36MN/AN/A

Tenzing Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Summary

Tenzing Acquisition beats Orgenesis on 5 of the 8 factors compared between the two stocks.

Get Tenzing Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for TZAC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TZAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TZAC vs. The Competition

MetricTenzing AcquisitionPharmaceutical Preparations Industry SectorNASDAQ Exchange
Market Cap$1.85M$812.96M$2.01B$9.05B
Dividend YieldN/A4.84%13.71%3.99%
P/E RatioN/A1.1512.1020.26
Price / SalesN/A230.412,026,446.21119.26
Price / Cash143.1023.4456.1028.59
Price / Book0.376.323.755.65
Net Income$620K-$27.99M-$302.05M$249.15M

Tenzing Acquisition Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TZAC
Tenzing Acquisition
N/A$0.36
-6.5%
N/A-66.4%$1.85MN/A0.00N/AGap Up
High Trading Volume
ORGS
Orgenesis
N/A$1.53
+3.7%
N/AN/A$7.34M$662K0.00150Gap Down
AEZS
Aeterna Zentaris
N/A$3.40
+1.8%
N/A-28.2%$6.10M$2.37M-0.2320
CPHI
China Pharma
0.3424 of 5 stars
$1.81
+1.1%
N/A-92.9%$5.90M$4.30M0.00250
NRBO
NeuroBo Pharmaceuticals
N/A$0.64
+2.1%
N/A-85.7%$5.54MN/A0.0010News Coverage
Gap Up
MTNB
Matinas Biopharma
N/A$0.90
+1.5%
N/AN/A$4.59MN/A-0.1930
CANF
Can-Fite BioPharma
3.2959 of 5 stars
$1.04
-1.0%
$14.00
+1,246.2%
-57.9%$3.68M$674K-0.588
NBY
NovaBay Pharmaceuticals
2.028 of 5 stars
$0.61
+5.0%
$0.85
+39.6%
-70.7%$3.54M$9.78M-0.0130Gap Up
SPRB
Spruce Biosciences
2.1655 of 5 stars
$0.07
-1.9%
$1.75
+2,361.3%
-87.3%$3.00M$4.91M-0.0820News Coverage
Gap Down
AFMD
Affimed
2.9524 of 5 stars
$0.18
-34.9%
$3.62
+1,895.9%
-96.4%$2.92M$877K0.00200Gap Down
High Trading Volume
GRAY
Graybug Vision
N/A$1.60
+11.9%
N/A-62.2%$2.51MN/A-0.9227High Trading Volume

Related Companies and Tools


This page (NASDAQ:TZAC) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners